Joel Kallich

3.7k total citations · 1 hit paper
58 papers, 2.9k citations indexed

About

Joel Kallich is a scholar working on Hematology, Oncology and Economics and Econometrics. According to data from OpenAlex, Joel Kallich has authored 58 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 18 papers in Oncology and 17 papers in Economics and Econometrics. Recurrent topics in Joel Kallich's work include Erythropoietin and Anemia Treatment (19 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Cancer survivorship and care (10 papers). Joel Kallich is often cited by papers focused on Erythropoietin and Anemia Treatment (19 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and Cancer survivorship and care (10 papers). Joel Kallich collaborates with scholars based in United States, United Kingdom and Germany. Joel Kallich's co-authors include Ron D. Hays, Donna Mapes, Stephen Joel Coons, William B. Carter, Anne M. McDermott, Xiao Xu, Caren Kamberg, April Teitelbaum, David Cella and Carly J. Paoli and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Joel Kallich

57 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument

1994 904 citations Ron D. Hays, Joel Kallich et al. Quality of Life Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel Kallich United States	23	1.2k	794	528	474	443	58	2.9k
Leslie R. Harrold United States	41	789 0.7×	776 1.0×	206 0.4×	757 1.6×	302 0.7×	168	6.9k
Alison M. MacLeod United Kingdom	32	3.7k 3.2×	560 0.7×	271 0.5×	333 0.7×	390 0.9×	117	5.6k
Eric D. Weinhandl United States	28	1.5k 1.3×	318 0.4×	188 0.4×	376 0.8×	199 0.4×	103	2.9k
Wenke Hwang United States	24	431 0.4×	613 0.8×	188 0.4×	116 0.2×	360 0.8×	64	2.3k
Brian D. Bradbury United States	29	1.8k 1.5×	250 0.3×	229 0.4×	902 1.9×	186 0.4×	88	3.3k
Guofen Yan United States	33	2.3k 1.9×	372 0.5×	111 0.2×	311 0.7×	385 0.9×	87	4.3k
David Naimark Canada	33	1.2k 1.0×	674 0.8×	274 0.5×	92 0.2×	330 0.7×	115	4.8k
Jiannong Liu United States	29	2.0k 1.7×	301 0.4×	165 0.3×	210 0.4×	246 0.6×	90	3.7k
Marije E. Hamaker Netherlands	38	383 0.3×	816 1.0×	1.4k 2.6×	195 0.4×	672 1.5×	148	4.4k
Keith McCullough United States	32	2.7k 2.3×	629 0.8×	159 0.3×	375 0.8×	765 1.7×	107	5.4k

Countries citing papers authored by Joel Kallich

Since Specialization

Citations

This map shows the geographic impact of Joel Kallich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Kallich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Kallich more than expected).

Fields of papers citing papers by Joel Kallich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Kallich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Kallich. The network helps show where Joel Kallich may publish in the future.

Co-authorship network of co-authors of Joel Kallich

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Kallich. A scholar is included among the top collaborators of Joel Kallich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Kallich. Joel Kallich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Parris, George E., et al.. (2020). Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Immunosuppressive Medications. Arthritis & Rheumatism. 72. 2–2. 1 indexed citations

Curtis, Jeffrey R., Fenglong Xie, Jonathan Kay, & Joel Kallich. (2019). Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. Arthritis Research & Therapy. 21(1). 285–285. 7 indexed citations

Wade, Sally, Jeffrey R. Curtis, Jingbo Yu, et al.. (2012). Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone. 50(4). 870–875. 50 indexed citations

Viswanathan, Hema N., Bradley S. Stolshek, John Adams, et al.. (2012). Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan. Osteoporosis International. 24(4). 1195–1206. 5 indexed citations

Xu, Yihua, Hema N. Viswanathan, John Adams, et al.. (2011). Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan. Journal of Evaluation in Clinical Practice. 19(1). 50–59. 8 indexed citations

Song, Xue, Nianwen Shi, Enkhe Badamgarav, et al.. (2011). Cost burden of second fracture in the US Health System. Bone. 48(4). 828–836. 39 indexed citations

Polsky, Daniel, et al.. (2009). The Importance of Clinical Variables in Comparative Analyses Using Propensity-Score Matching. PharmacoEconomics. 27(9). 755–765. 10 indexed citations

Berger, Ariel, John Edelsberg, Joel Kallich, & Gerry Oster. (2008). Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia. Clinical Therapeutics. 30(1). 206–218. 9 indexed citations

Littlewood, Timothy J., Joel Kallich, Jesús F. San Miguel, Lisa Hendricks, & Michael Hedenus. (2006). Efficacy of Darbepoetin Alfa in Alleviating Fatigue and the Effect of Fatigue on Quality of Life in Anemic Patients with Lymphoproliferative Malignancies. Journal of Pain and Symptom Management. 31(4). 317–325. 33 indexed citations

10.

Meehan, Kenneth R., N. Simon Tchekmedyian, Robert E. Smith, & Joel Kallich. (2006). Resource Utilisation and Time Commitment Associated with Correction of Anaemia in Cancer Patients Using Epoetin Alfa. Clinical Drug Investigation. 26(10). 593–601. 12 indexed citations

11.

Houts, Arthur C., et al.. (2006). Patient and caregiver time burden associated with anaemia treatment in different patient populations. Supportive Care in Cancer. 14(12). 1195–1204. 12 indexed citations

12.

Lyman, Gary H., Ernst R. Berndt, Joel Kallich, et al.. (2005). The Economic Burden of Anemia in Cancer Patients Receiving Chemotherapy. Value in Health. 8(2). 149–156. 58 indexed citations

13.

Berndt, Ernst R., William H. Crown, Joel Kallich, et al.. (2005). The Impact of Anaemia and its Treatment on Employee Disability and Medical Costs. PharmacoEconomics. 23(2). 183–192. 22 indexed citations

14.

Cella, David, Joel Kallich, Anne M. McDermott, & Xiao Xu. (2004). The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Annals of Oncology. 15(6). 979–986. 185 indexed citations

15.

Tchekmedyian, N. Simon, Joel Kallich, Anne M. McDermott, Peter Fayers, & Moshe H. Erder. (2003). The relationship between psychologic distress and cancer‐related fatigue. Cancer. 98(1). 198–203. 65 indexed citations

16.

Revicki, Dennis A., Karen Gold, Dennis W. Buckman, et al.. (2001). Imputing Physical Health Status Scores Missing Owing to Mortality. Medical Care. 39(1). 61–71. 14 indexed citations

17.

Rao, Sumati, William B. Carter, Donna Mapes, et al.. (2000). Development of subscales from the symptoms/problems and effects of kidney disease scales of the kidney disease quality of life instrument. Clinical Therapeutics. 22(9). 1099–1111. 40 indexed citations

18.

Meehan, Kenneth R., et al.. (2000). Platelet transfusions: Utilization and associated costs in a tertiary care hospital. American Journal of Hematology. 64(4). 251–256. 79 indexed citations

19.

Hays, Ron D., et al.. (1994). Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument. Quality of Life Research. 3(5). 329–338. 904 indexed citations breakdown →

20.

Kallich, Joel, et al.. (1993). Vascular Access Procedures for End-Stage Renal Disease Medicare Beneficiaries. 56(7). 1237–1237. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact